Sanjay W. Pimplikar

Este archivo solo abarca los artículos del autor incorporados a este sitio a partir del 1 de diciembre de 2006. Para fechas anteriores realice una búsqueda entrecomillando su nombre.

A panel of medical experts from the National Institute on Aging and the Alzheimer’s Association last week proposed changes in the way doctors diagnose Alzheimer’s disease — including the use of so-called biomarkers, tests like PET brain scans and analyses of spinal fluids to promote early detection of the disease. Although these recommendations are well intentioned, evidence suggests that it would be a mistake to adopt them at this time. To understand why, it’s important to recognize what these tests mean, in what context the information will be used and what experience has shown us.

First, about the diagnostic tests: A PET scan detects clumps of a deformed protein called amyloid beta, commonly known as plaques.…  Seguir leyendo »